Arena Turns In FDA Application
Luke Timmerman12/22/09
San Diego-based Arena Pharmaceuticals (NASDAQ: ARNA) said today it has filed its application to the FDA for clearance to start marketing lorcaserin for weight loss. The application includes information on 18 clinical trials that enrolled almost 8,600 patients, including the pivotal trials known as Bloom and Blossom. The company had forecasted previously it would complete the application by the end of 2009.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.





Lorcaserin
12/22/09 1:01 pm
I have been reading that Lorcaserin is similar to fenfluramine but has not shown any of the heart value problems that fenfluramine had. It also looks like the lesser of the side effects of some of the newer obesity meds on the horizen. What about doctors prescribing Lorcaserin with Phentermine. Have there been any studies on that?